• Opus Genetics today appointed Andrew Murphy chief scientific officer.
• Murphy previously served as senior vice president of research and early development at Kriya Therapeutics, leading AAV vector research.
• Jamie Lynne Hart was appointed executive director, executive operations.
• Hart previously served as chief of staff to the CEO at Apellis Pharmaceuticals, now Biogen, supporting corporate strategy and portfolio prioritization.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Opus Genetics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610290700PRIMZONEFULLFEED9855883) on October 29, 2026, and is solely responsible for the information contained therein.